Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1575 | Fostamatinib Wiki | 1.00 |
| drug3403 | Ruxolitinib Wiki | 0.32 |
| drug3738 | Standard of care Wiki | 0.20 |
Navigate: Correlations HPO
There is one clinical trial.
The aim of the study will be to determine the epidemiological and clinical features of COVID-19 cases, immunological and virological courses, interaction with nutritional status, and response to treatment for COVID-19 patients admitted to treatment centers in Ethiopia. Methods: This multi-site cohort enrolls, patients with confirmed COVID-19 infection admitted to treatment centers will be enrolled irrespective of their symptoms and followed up for 12 months. Baseline epidemiological, clinical, laboratory and imaging data will be collected from treatment records, interviews, physical measurements and biological samples. Endline data involves treatment and prognostic outcomes to be measured using different biomarkers and clinical parameters, The patients will be followed up in the selected treatment centers for COVID-19 infection. For all data collected both descriptive and multivariable analyses will be performed to isolated determinants of the treatment outcome and prognosis to generate relevant information for informed prevention and case management.
Description: Number patients developing severe infection or death
Measure: Number of patients survival or death Time: 12 monthsDescription: Mean rate of recovery in patients with diagnosis of COVID-19
Measure: Rate of recovery time Time: 4 weeksDescription: proportion of shedding detected in environment and personal protective equipment
Measure: Viral shedding Time: 6 weeksDescription: quantity of viral load
Measure: Viral loads Time: 12 monthsDescription: clinical manifestations Proportions of mild, moderate, severe and critical cases
Measure: Clinical symptoms and signs Time: 12 monthsDescription: Force exerted by the blood against the walls of the vessels (arteries) as it is pumped by the heart. Measurement using the multi-parameter vital signs monitor. Units of measurement in mmHg. Obtain systolic and diastolic pressure.
Measure: Blood pressure Time: 4 weeksDescription: Prevalence of severe forms among all COVID-19 patients with diabetes
Measure: Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19 Time: 4 weeksDescription: proportion of patients with cancer and COVID-19 postive
Measure: Assess the prevalence of severe forms among hospitalized patients with cancer and COVID-19 Time: 4 weeksDescription: TC, TG, HDL-C, and LDL-C
Measure: Lipid Profiles Time: 12 monthsDescription: Prevalence of inadequate intake of zinc, Iron and Vitamin A
Measure: Assess the prevalence of nutrient intakes Time: 12 monthsDescription: Prevalence of Vitamin D, zinc, and Iron deficiency anemia measured in serum
Measure: Assess the prevalence of micronutrients deficiencies among hospitalized patients with COVID-19 Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports